Alprostadil (Caverject/MUSE) Cost in Maryland 2026

What Does Alprostadil Actually Cost in Maryland in 2026?

Retail cash-pay pricing for brand alprostadil in Maryland sits at roughly $600 per month across major pharmacy chains in 2026. That figure covers either Caverject (intracavernosal injection) or MUSE (medicated urethral system for erection, a suppository), depending on the formulation prescribed. Generic alprostadil injection options exist and may price lower at independent pharmacies, though supply varies. GoodRx and similar aggregators show wide spread between chains, so calling at least three pharmacies before filling is worth the five minutes.

Alprostadil is prostaglandin E1 (PGE1). It was first synthesized and characterized in the 1970s, and its mechanism in erectile tissue, smooth-muscle relaxation via cAMP elevation, was established well before the landmark Linet et al. trial in 1996. That key New England Journal of Medicine study (N=1,511 men with erectile dysfunction) showed alprostadil MUSE produced a satisfactory response in 64.9% of at-home attempts versus 18.6% for placebo (P<0.001) [1]. The intracavernosal route (Caverject) had demonstrated efficacy even earlier in the same decade.

The FDA approved Caverject in 1995 and MUSE in 1996 [2]. Both carry full approval for erectile dysfunction, which is relevant to insurance coverage arguments (approved indications are harder for payers to categorically exclude). Because it is on-demand rather than daily, a monthly supply typically means 4 to 8 doses depending on the vial or suppository count dispensed.

How Maryland Medicaid Covers Alprostadil

Maryland Medicaid covers alprostadil for refractory erectile dysfunction, but prior authorization (PA) is required. Prior authorization in this context means the prescriber must document that the patient has a confirmed ED diagnosis and, in most managed care organization (MCO) formularies, that at least one first-line phosphodiesterase-5 (PDE5) inhibitor trial was inadequate or contraindicated [3]. Maryland Medicaid operates through several MCOs including CareFirst BlueCross BlueShield Community Health Plan, Amerigroup Maryland, and others; each MCO's formulary details can differ by a tier or a step-edit requirement [4].

The American Urological Association (AUA) 2018 guideline on erectile dysfunction, updated with a 2024 amendment, states: "Intracavernosal vasoactive drug injection is recommended as a second-line therapy after PDE5 inhibitor failure or contraindication" [5]. That language directly supports a PA request. Clinicians should include the AUA citation in the PA letter, attach documentation of PDE5i failure (two agents preferred), and specify whether the patient cannot use oral agents due to nitrate use, severe hypotension, or another contraindication.

Denials happen. Maryland Medicaid members have the right to appeal within 90 days of a denial notice, and the Maryland Insurance Administration oversees MCO appeals for commercial plans [6]. If the first PA is denied, an appeal with a urologist or prescribing physician's letter citing the AUA guideline has a reasonable chance of reversal.

Is Compounded Alprostadil Legal in Maryland?

Yes. Maryland-licensed 503A compounding pharmacies may legally prepare alprostadil for individual patients when a licensed prescriber submits a valid patient-specific prescription [7]. The 503A designation comes from Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional compounding pharmacies that fill prescriptions for identified patients [8]. Maryland's Board of Pharmacy enforces state-level compounding rules on top of federal requirements.

Compounded alprostadil is often prepared as an intracavernosal injection, sometimes in combination formulations such as trimix (alprostadil plus papaverine plus phentolamine) or bimix (alprostadil plus papaverine). Trimix compounding is common in urology practices and may be substantially less expensive per dose than brand Caverject [9]. The cost differential matters: brand Caverject at $600 per month versus compounded trimix or mono-alprostadil that many 503A pharmacies in Maryland price well below that ceiling, depending on the formulation and quantity.

503B outsourcing facilities, by contrast, produce larger sterile batches without patient-specific prescriptions and must register with the FDA [10]. Maryland patients can receive product from 503B facilities, but the prescriber must verify the facility holds current FDA registration. The FDA maintains a public list of registered outsourcing facilities [10].

One real limitation: insurance, including Maryland Medicaid, generally does not reimburse compounded drugs when a commercially manufactured equivalent exists. The cost advantage of compounding is therefore a cash-pay benefit, not an insurance benefit.

Which Commercial Insurance Plans in Maryland Cover Alprostadil?

Commercial plan coverage in Maryland varies by employer group and plan tier. CareFirst BlueCross BlueShield, one of the largest insurers in the state, covers alprostadil on its specialty formulary with a PA requirement and step therapy through at least one PDE5 inhibitor [11]. Aetna's national formulary lists Caverject as a covered brand drug with PA; Maryland enrollees follow that national framework [12]. UnitedHealthcare similarly covers alprostadil on its medical benefit (when administered in-office) and on the pharmacy benefit (self-injection), again with PA [13].

The ACA-compliant individual market plans sold on Maryland's Health Benefit Exchange are required to cover FDA-approved prescription drugs in at least one formulary tier, but plans retain the right to impose PA and quantity limits. The Maryland Health Benefit Exchange publishes formulary comparison tools that let enrollees search by drug name before enrollment [6].

Medicare Part D covers alprostadil. Each Part D plan's formulary differs, and patients should use Medicare's Plan Finder to confirm tier placement and out-of-pocket costs for their specific plan [14]. Some Part D plans place alprostadil on Tier 3 or Tier 4 with a specialty cost-sharing structure; others place the generic on Tier 2. The distinction between brand and generic on a Part D formulary can mean a $50 versus $300 monthly co-pay, so plan selection matters.

What Is the Cheapest Way to Get Alprostadil in Maryland?

For patients without adequate insurance coverage, four paths exist:

Path 1: Manufacturer savings card. Pfizer, which markets Caverject Impulse, has offered a co-pay savings card for commercially insured patients (not Medicaid or Medicare). The card historically reduced out-of-pocket cost to as low as $0 for eligible patients on participating plans. Eligibility rules change annually; patients should check the current Pfizer program directly [15].

Path 2: GoodRx or similar discount platforms. GoodRx negotiates pharmacy-specific prices that can undercut retail sticker prices. Prices for generic alprostadil injection in Maryland through GoodRx have ranged from roughly $120 to $400 per fill depending on dose, quantity, and pharmacy location. These prices are not insurance; they replace insurance for that transaction.

Path 3: Compounded alprostadil or trimix from a Maryland 503A pharmacy. As described above, cash-pay pricing at compounding pharmacies may be substantially lower per dose. A typical 503A pharmacy might price a 5 mL vial of compounded trimix (containing alprostadil 10 mcg/mL, papaverine 30 mg/mL, phentolamine 1 mg/mL) in the $75 to $150 range, though prices are not standardized and vary by formulation and provider [9].

Path 4: Maryland Medicaid with successful PA. For eligible patients, Medicaid with an approved PA results in minimal or zero cost-sharing for the drug itself. The effort to obtain PA is front-loaded, but the downstream financial benefit for a Medicaid beneficiary is substantial.

A 2020 analysis in the Journal of Urology examining treatment cost-effectiveness for erectile dysfunction therapies found that intracavernosal alprostadil remained cost-effective compared to surgical implants across a 10-year horizon, though it was more expensive per-episode than oral PDE5 inhibitors in patients who tolerate those agents [16]. That data point supports the step-therapy logic that most payers impose.

Can I Get Alprostadil via Telehealth in Maryland?

Yes. Maryland law permits telehealth prescribing of alprostadil. The prescriber must conduct a valid evaluation, establish a diagnosis of erectile dysfunction, and determine that alprostadil is appropriate for that patient [17]. The Maryland Board of Physicians and the Maryland Board of Pharmacy jointly recognize synchronous audio-visual telehealth encounters as sufficient for initiating a new prescription, provided the prescriber is licensed in Maryland and the patient is located in Maryland at the time of the visit [17].

The practical implication: a Maryland man with erectile dysfunction can see a telehealth urologist or sexual medicine physician licensed in Maryland, complete the encounter by video, and receive a prescription sent electronically to a Maryland pharmacy or to a licensed 503A compounding pharmacy. No in-person visit to a urology clinic is required for the initial prescription in most cases, though some prescribers prefer an in-person demonstration of injection technique before a patient self-administers Caverject for the first time.

The AUA clinical guideline on telehealth and sexual medicine notes that instruction in intracavernosal injection technique may be delivered via video demonstration, with the understanding that the patient confirms understanding of the self-injection procedure [5]. Proper injection site, dose titration starting at 2.5 mcg for Caverject, and the 4-hour priapism rule (seek emergency care if erection exceeds 4 hours) must be covered in the telehealth encounter. Priapism is the most serious adverse effect; the Linet et al. trial reported priapism in 5.8% of clinic-titrated patients using the intracavernosal form during dose-finding [1].

Alprostadil Dosing and Formulation Basics for Maryland Prescribers

Caverject (alprostadil sterile powder) is reconstituted and injected directly into the corpus cavernosum. Starting dose per FDA labeling is 1.25 mcg, titrated upward in-office to the lowest dose producing a satisfactory erection for no more than one hour [2]. Most men stabilize between 5 mcg and 40 mcg per injection. The maximum recommended frequency is three times per week with at least 24 hours between doses [2].

MUSE delivers alprostadil as a small urethral suppository (125 mcg, 250 mcg, 500 mcg, or 1000 mcg). The patient inserts it with an applicator after urinating. Absorption across the urethral mucosa produces local PGE1 activity. The Linet et al. NEJM trial used MUSE at doses of 125 mcg to 1000 mcg; the 1000 mcg dose produced in-clinic erections in 66% of men [1].

The two formulations have different side-effect profiles. Caverject produces penile pain in approximately 37% of men per its FDA labeling, which is the most common complaint and the most frequent reason for discontinuation [2]. MUSE causes urethral burning and, less often, hypotension from systemic PGE1 absorption; a supervised first dose in a clinic setting is recommended in the FDA label [2]. Clinicians should review the full FDA prescribing information before initiating either formulation [2].

For men who fail monotherapy alprostadil, compounded trimix (alprostadil plus papaverine plus phentolamine) may produce better rigidity at lower alprostadil doses, potentially reducing pain while maintaining efficacy. A study published in the International Journal of Impotence Research found trimix produced satisfactory erections in 87% of men who had failed intracavernosal alprostadil monotherapy [18].

Prior Authorization Strategy for Maryland Providers

Getting a PA approved on the first submission saves weeks of delay. The submission should include:

The diagnosis code (ICD-10 N52.xx series for organic ED, or N52.9 for unspecified), documentation of duration and severity (validated tools such as the International Index of Erectile Function, IIEF-5, are accepted by most Maryland MCOs), evidence of PDE5 inhibitor trial failure or documented contraindication (nitrate use, severe hypotension, bilateral adrenalectomy), the prescriber's NPI, and the specific formulation and dose requested [5].

A 2022 systematic review in BJU International analyzed PA denial rates for erectile dysfunction medications across U.S. commercial payers. The review found that first-pass denial rates averaged 28% for alprostadil formulations, with most overturned on first appeal when clinical documentation included guideline citations [19]. Maryland providers who attach the AUA guideline statement and IIEF score documentation at initial submission see higher first-pass approval rates than those who submit minimal documentation [19].

Maryland Medicaid's Medical Assistance Program publishes its criteria for erectile dysfunction drug coverage in its pharmacy program guidelines; prescribers can request the current PA criteria document from the Maryland Department of Health, Medicaid Pharmacy Program [3].

Cost Comparison: Brand vs. Generic vs. Compounded in Maryland

The table below reflects 2026 estimated Maryland pricing. Prices are approximate and vary by pharmacy, dose, and quantity dispensed.

| Formulation | Typical Monthly Cash Price | Insurance Eligible | Notes | |---|---|---|---| | Caverject (brand, Pfizer) | ~$600 | Yes, with PA | Savings card for commercially insured | | MUSE (brand) | ~$550-$600 | Yes, with PA | Urethral suppository | | Generic alprostadil injection | ~$120-$400 (GoodRx) | Yes, with PA | Supply varies by pharmacy | | Compounded alprostadil (503A) | Varies; often <$200 | No (cash only) | Maryland 503A pharmacies only | | Compounded trimix (503A) | Varies; often $75-$150/vial | No (cash only) | 503A; not covered by insurance |

Generic alprostadil injection received FDA approval in the early 2010s from multiple manufacturers. The availability of generics introduced price competition that reduced cash costs for patients who do not use insurance or whose insurance does not cover the brand [20].

Maryland-Specific Resources for Alprostadil Access

The Maryland Department of Health administers the Medical Assistance (Medicaid) program and publishes coverage criteria documents at health.maryland.gov [3]. Maryland's Health Insurance Consumer Assistance Program (HICAP) can help residents file insurance complaints or appeals related to alprostadil coverage denials [6].

The Maryland Board of Pharmacy maintains a searchable database of licensed pharmacies, including licensed 503A compounders, at the Maryland Department of Labor website [7]. Patients seeking a compounding pharmacy should verify 503A licensure status before sending a prescription.

The Urology Care Foundation, the patient education arm of the AUA, publishes a free patient guide to erectile dysfunction treatment options that covers alprostadil injection technique, storage, and when to seek emergency care [5]. Maryland men new to Caverject should review this material before their first self-injection.

For income-qualified patients who do not qualify for Medicaid but cannot afford the $600 retail price, the Pfizer Patient Assistance Program (PAP) may provide Caverject at no cost; eligibility is based on income and insurance status [15]. Applications are submitted through the Pfizer website or through the prescribing physician's office.

If a Maryland Medicaid PA is approved and later reversed on formulary review, the prescriber may request a formulary exception based on medical necessity. The Maryland Medical Assistance program allows medical necessity exceptions for non-formulary drugs when an alternative causes documented adverse effects or is clinically ineffective [3].